» Articles » PMID: 12957285

Dimerization Contributes to Oncogenic Activation of MLL Chimeras in Acute Leukemias

Overview
Journal Cancer Cell
Publisher Cell Press
Specialty Oncology
Date 2003 Sep 6
PMID 12957285
Citations 74
Authors
Affiliations
Soon will be listed here.
Abstract

MLL is a histone methyltransferase that can be converted into an oncoprotein by acquisition of transcriptional effector domains following heterologous protein fusions with a variety of nuclear transcription factors, cofactors, or chromatin remodeling proteins in acute leukemias. Here we demonstrate an alternative mechanism for activation of MLL following fusions with proteins (AF1p/Eps15 and GAS7) that normally reside in the cytoplasm. The coiled-coil oligomerization domains of these proteins are necessary and sufficient for leukemogenic transformation induced by the respective MLL fusion proteins. Furthermore, homodimerization of MLL by synthetic dimerization modules mimics bona fide MLL fusion proteins resulting in Hox gene activation and enhanced self-renewal of hematopoietic progenitors. Our studies support an oligomerization-dependent mechanism for oncogenic conversion of MLL, presumably in part by recruitment of accessory factors through the dimerized MLL moiety of the chimeric protein.

Citing Articles

Engineering an inducible leukemia-associated fusion protein enables large-scale ex vivo production of functional human phagocytes.

Windisch R, Soliman S, Hoffmann A, Chen-Wichmann L, Danese A, Vosberg S Proc Natl Acad Sci U S A. 2024; 121(25):e2312499121.

PMID: 38857395 PMC: 11194515. DOI: 10.1073/pnas.2312499121.


Krüppel-like Factor 4 Supports the Expansion of Leukemia Stem Cells in MLL-AF9-driven Acute Myeloid Leukemia.

Lewis A, Bridges C, Moorshead D, Chen T, Du W, Zorman B Stem Cells. 2022; 40(8):736-750.

PMID: 35535819 PMC: 9406610. DOI: 10.1093/stmcls/sxac033.


Transcriptional addiction in mixed lineage leukemia: new avenues for target therapies.

Xiao R, Wang H, Liang K Blood Sci. 2022; 1(1):50-56.

PMID: 35402805 PMC: 8975088. DOI: 10.1097/BS9.0000000000000011.


PML nuclear body biogenesis and oligomerization-driven leukemogenesis.

Li Y, Ma X, Meng G Blood Sci. 2022; 2(1):7-10.

PMID: 35399865 PMC: 8975047. DOI: 10.1097/BS9.0000000000000034.


KMT2A-CBL rearrangements in acute leukemias: clinical characteristics and genetic breakpoints.

Bataller A, Guijarro F, Caye-Eude A, Strullu M, Sterin A, Molina O Blood Adv. 2021; 5(24):5617-5620.

PMID: 34638131 PMC: 8714718. DOI: 10.1182/bloodadvances.2021005736.